arteriolar dilator). Cerebral metabolites in white matter were measured by proton MR spectroscopy. We also studied the 12 age-and gendermatched normontensives.
P-333 ARGININE-AMINOPEPTIDASE IN RAT CARDIAC FIBROBLASTS PARTICIPATES IN ANGIOTENSIN TURNOVER
Unit, University of Leuven (K.U.Leuven) , Leuven, Vlaams Brabant, Belgium. The aim of this study was to elucidate the presence in rat cardiac fibroblasts of Arginine-aminopeptidase and its involvement in the hydrolysis of angiotensin peptides. Peptidase activity was measured as hydrolysis of synthetic substrates , aryl-p-nitroanilides, and the appearance of nitroaniline. Immunoblottings were performed with antibodies to aminopeptidase B. Arg-aminopeptidase found in cardiac fibroblasts was arginine and lysine specific, sensitive to various aminopeptidase inhibitors and to the inhibitor of metalloproteases, 1,10-phenantroline. Experiments with arphamenine A, a specific inhibitor of aminopeptidase B, have shown the presence of two Arg-aminopeptidase activities : arphameninesensitive: chloride-stimulated aminopeptidase and arphamenine-insensitive : chloride-insensitive aminopeptidase. TGF-beta1 (400 pmol/L) stimulated both Arg-aminopeptidase activities by 3-fold. Immunoblot with an antibody specific to rat aminopeptidase B has revealed that arphamenine-sensitive: chloride-stimulated aminopeptidase is anminopeptidase B. Arginine-p-nitroanilide hydrolysis was significantly inhibited by angiotensin peptides such as angiotensin (1-10), (1-8), (1-7), (1-4), (5-8), (4 -8), (3-8) and (2-8) at a concentration of 50 micromol/L, which was 4-fold less than the Arginine-p-nitroanilide concentration. Our data suggest that chloride-insensitive Arginine-aminopeptidase could contribute to the hydrolysis of all studied angiotensin peptides in concert with other peptidases present in fibroblasts. Some of the peptides could probably not be hydrolyzed by Arginine-aminopeptidase.Instead, they could be firstly hydrolyzed by another peptidase present in fibroblasts and the product of this hydrolysis could be a substrate for Arginine-aminopeptidase. The purpose of this investigation was to determine whether aminopeptidase (AP)-inhibition could affect the angiotensin II (Ang II)-stimulated collagen gel contraction in basal (control) and TGF-beta1-treated cardiac fibroblasts (or myofibroblasts). The tested AP-inhibitors were the broad range AP-inhibitor bestatin, the specific inhibitor of Alanine-AP leuhistin and the specific inhibitor of Arginine-AP arphamenine A. Cardiac fibroblasts (from normal male adult rats) from passage 2 were cultured to confluency and incubated with(out) 400 pmol/L TGF-beta1 in Dulbecco's Modified Eagle's Medium (DMEM) with 10% foetal bovine serum (FBS). These fibroblasts were further incubated in a floating collagen gel lattice with the tested products for 3 days in DMEM without FBS.The contraction of the collagen gel lattice by cardiac fibroblasts was determined by measuring the gel volume with titriated water. Ang II (0.1 microM) reduced the gel volume in control and TGF-beta1-treated fibroblasts. The Ang II-stimulated collagen gel contraction in control and TGF-beta1-treated fibroblasts was completely reversed by leuhistin and arphamenine A (100 microM). Bestatin (100 microM) only partially inhibited the Ang II-stimulated collagen gel contraction in control fibroblasts while it did not affect the Ang II-induced contraction in TGFbeta1-treated fibroblasts. In control and TGF-beta1-treated fibroblasts, 100 microM leuhistin or arphamenine A only partially inhibited Alanine-AP activity, while bestatin (100 microM) completely inhibited the Alanine-AP activity. Arginine-AP activity was only partially inhibited by leuhistin and arphamenine A at 100 microM in control and TGF-beta1-treated fibroblasts. Bestatin (100 microM), however, completely blocked the Arginine-AP activity in control fibroblasts and only partially in TGF-beta1-treated fibroblasts. . Our data suugest that both Alanine-and Arginine-AP are involved in the reversal of the Ang II-stimulated collagen gel contraction in control and TGF-beta1-treated cardiac fibroblasts or myofibroblasts. The objective of this study was to determine whether the angiotensin converting enzyme (ACE) inhibitor lisinopril and the aminopeptidase inhibitor with a broad specificity bestatin could affect the collagen production in basal and TGF-beta1-treated cardiac fibroblasts. Cardiac fibroblasts (from 5 normal male adult rats) from passage 2 were cultured to confluency, incubated with(out) 600 pmol/L TGF-beta1 for 2 days in serum-free Dulbecco's Modified Eagle's Medium and further incubated with the tested products (lisinopril or bestatin) for 1 day in this serumfree medium with ascorbic acid , beta-aminoproprionitrile and titriated proline. Soluble collagen was measured in the conditioned medium and nonsoluble collagen in the cell layer. Lisinopril dose-dependently reduced ACE-activity in basal and TGF-beta1-treated cardiac fibroblasts. Bestatin inhibited the basal and TGF-beta1-stimulated aminopeptidase activity in a concentration dependent manner. Lisinopril (10 microM) decreased (pϽ0.05) the soluble collagen production from 882Ϯ160 (meanϮSEM) to 658Ϯ142 dpm/ng DNA and the nonsoluble collagen production from 267Ϯ65 to 193Ϯ45 dpm/ng DNA in basal cardiac
